Toronto, Ontario--(October 20, 2021) - Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTCQB: DTMXF) (the "Company" or "Datametrex") is pleased to announce that its wholly-owned subsidiary Medi-Call MD Inc, ("Medi-Call") has officially launched a closed beta test for its Medi-Call health app, a comprehensive mobile application for patients, enabling Canadians to visit a doctor through their smartphone. Selected beta testers will be able to load the app on their mobiledevice. The closed beta test will be previewed in a webinar on Thursday, October 28th. The details of the webinar and how to attend will be posted on Datametrex.com in the next few days.
The Medi-Call app is a subscription service that connects patients with doctors, providing technology-driven e-health or m-health care services including prescriptions. Patients download the app and sign up by entering past medical history, current symptoms and a designated pharmacy where patients pick up a prescription. The patient will be connected to our certified doctors via chat and video call and following any diagnosis, a prescription will be provided if needed and sent to the patient's designated pharmacy.
The app provides accessible healthcare to people who live in rural or isolated communities and make services more readily available and convenient for people with limited time, mobility, or transportation choices.
Once fully released, the App will be available free in both the Apple App Store and the Google Play store.
"Medi-Call app is leveraging advanced technology to help bring accessible, affordable healthcare services to patients with doctors supporting Canadians to take greater ownership of their health and wellness outcomes outside of doctor offices and emergency rooms leading to improved health," stated Marshall Gunter, CEO of Datametrex. "Dr. Omar Sharif and his team at Medi-Call worked closely with the developers to provide another entry point to healthcare and consultation, which improves the patient's experience."
About Medi-Call Md Inc.
Medi-Call is an enhanced telemedicine company providing technology-driven e-health or m-health care services including prescriptions, launching initially in British Columbia, and then expanding across Canada. The objectives of Medi-Call, include making health care accessible to people who live in rural or isolated communities and make services more readily available or convenient for people with limited time, mobility, or transportation choices. Medi-Call is driven to improve coordination and communication of treatment among members of a health care team and its patients.
Datametrex AI Limited is a technology-focused company with exposure to Artificial Intelligence and Machine Learning through its wholly-owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex's mission is to provide tools that support companies in fulfilling their operational goals, including Health and Safety, with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, Company provides progressive solutions to support the supply chain.
For additional information on Datametrex and other corporate information, please visit the Company's website at www.datametrex.com.
For further information, please contact: Marshall Gunter - CEO Phone: (514) 295-2300 Email: email@example.com
Neither the TSX Venture Exchange nor it's Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
All statements included in this press release that address activities, events, or developments that the Company expects, believes, or anticipates will or may occur in the future are forward-looking statements. These forward-looking statements involve numerous assumptions made by the Company based on its experience, perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances. In addition, these statements involve substantial known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections, and other forward-looking statements will prove inaccurate, certain of which are beyond the Company's control. In particular, there is no guarantee that the parties will successfully negotiate and enter into a definitive agreement on mutually acceptable terms or complete the Transaction in the manner contemplated herein, if at all, that the due diligence of any of the parties will be satisfactory, or that the parties will obtain any required board, shareholder, third-party and/or regulatory or other governmental approvals, if any. Readers should not place undue reliance on forward-looking statements. Except as required by law, the Company does not undertake to revise or update these forward-looking statements after the date hereof or revise them to reflect the occurrence of future unanticipated events.